Lymphoma, Non-HodgkinPhase 1/2RELATIVITY-069NCT05255601
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
A Phase 1/2 study testing Relatlimab and Nivolumab in people with Lymphoma, Non-Hodgkin and Hodgkin Disease, run by Bristol-Myers Squibb at 51 sites in 7 countries.
Trial summary
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. Read more about this study
- Who is it for?
- Ages Up to 30 years
- Conditions the study is for
- Lymphoma, Non-Hodgkin, Hodgkin Disease
- What is being tested?
- Relatlimab and Nivolumab
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 51 sitesin 7 countries
- Study dates
- 13 Sep 2022to 3 Dec 2025
- Phase
- Phase 1/2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 30 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Participants with pathologically confirmed high-risk R/R cHL, after non-response to or failure of 1or more lines of standard therapy.
- Participants with pathologically confirmed R/R NHL after non-response to or failure of 1or more lines of standard therapy, including, but not limited to, R/R primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).
- Participants with pathologically confirmed R/R NHL after non-response to or failure of 2 or more lines of standard therapy, including Burkitt lymphoma (blast count <25% malignant Burkitt cells and/or per the investigator's clinical assessment of risk status), lymphoblastic lymphoma (blast count < 25% of marrow nucleated cells and/or per the investigator's clinical assessment of risk status), NK/T-cell lymphoma (nasal and non-nasal NK/T-cell lymphoma subtypes, but not aggressive NK/T-cell leukemia/lymphoma subtype).
- The participant's current disease state must be R/R to standard therapy.
- Participants must have measurable PET positive disease in both cHL and NHL cohorts.
Who cannot join
- Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding.
- Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies.
- Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents.
- Participants with clinically significant systemic illnesses unrelated to the cancer as judged by the investigators, which would compromise the participant's ability to tolerate the study treatment.
- Participants with autoimmune disease.
- Prior allogeneic bone marrow transplantation.
- Other protocol-defined inclusion/exclusion criteria apply
Trial locations and contacts
51 sites in 7 countries.
51 sites in 7 countries
United States13 sites
Local Institution - 0029
Austin, Texas, 78723
Local Institution - 0073
Baltimore, Maryland, 21287
Local Institution - 0077
Birmingham, Alabama, 35233
Local Institution - 0066
Fort Myers, Florida, 33908
Local Institution - 0071
Hackensack, New Jersey, 07601
Local Institution - 0020
Jackson, Mississippi, 39216
Local Institution - 0025
Minneapolis, Minnesota, 55454
Local Institution - 0032
New Haven, Connecticut, 06510
Local Institution - 0060
New York, New York, 10032
Local Institution - 0035
Palo Alto, California, 94304
Local Institution - 0024
Phoenix, Arizona, 85016
Local Institution - 0026
San Antonio, Texas, 78207
Local Institution - 0059
Valhalla, New York, 10595
Italy10 sites
Local Institution - 0010
Aviano, 33081
Azienda Ospedaliero Universitaria di Bologna
Bologna, 40138
Local Institution - 0040
Florence, 50139
Fondazione IRCCS Istituto Nazionale Dei Tumori
Milan, Milano, 20133
Local Institution - 0070
Milan, 20162
Fondazione MBBM - Clinica Pediatrica
Monza, 20900
Azienda Ospedale Universita Padova
Padova, 35128
Local Institution - 0041
Pavia, 27100
Local Institution - 0002
Roma, 00165
Local Institution - 0004
Turin, 10126
Spain10 sites
Local Institution - 0046
Barcelona, 08035
Local Institution - 0069
Esplugues de Llobregat, Barcelona, 08950
Local Institution - 0030
Madrid, Madrid, 28009
Local Institution - 0058
Madrid, 28027
Local Institution - 0044
Madrid, 28040
Local Institution - 0055
Madrid, 28041
Local Institution - 0045
Madrid, 28046
Local Institution - 0062
Pamplona, 31008
Local Institution - 0023
Seville, 41013
Local Institution - 0049
Valencia, 46026
France9 sites
CHU dAngers - Pole Pediatrie
Angers, Angers Cedex 9, 49933
Groupe Hospitalier Pellegrin - Hopital des enfants
Bordeaux, 33076
Local Institution - 0033
Caen, 14033
Local Institution - 0067
La Tronche, 38700
Institut d Hematologie et d Oncologie Pediatriques
Lyon, 69373 Cedex 08
Centre Hospitalier Universitaire de Montpellier CHU Montpellier - Hopital Arnaud de Villeneuve
Montpellier, 34295
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Armand-Trousseau
Paris, 75571
Assistance Publique-Hopitaux de Paris AP-HP - Hopital Universitaire Robert-Debre
Paris, 75935
CHRU de Strasbourg-Hopital de Hautepierre
Strasbourg, 67000
United Kingdom5 sites
Local Institution - 0075
Cambridge, Cambridgeshire, CB2 0QQ
Local Institution - 0074
Liverpool, England, L12 2AP
Local Institution - 0054
London, Londonderry, NW1 2PG
Local Institution - 0053
London, SM2 5PT
Local Institution - 0068
Newcastle upon Tyne, Tyne and Wear, NE1 4LP
Australia3 sites
Local Institution - 0042
Nedlands, Western Australia, 6009
Local Institution - 0037
Randwick, New South Wales, 2031
Royal Childrens Hospital RCH - Queensland Childrens Hospital
South Brisbane, Queensland, 4101
Netherlands1 site
Princess Maxima Center for pediatric oncology
Utrecht, 3584 CS
About this study
Official title: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Disease
- Being tested
- Relatlimab, Nivolumab
- Keywords
- Pediatric, Lymphoma, Non-Hodgkin, Hodgkin Disease, Relatlimab, Nivolumab, Lymphocyte Activation Gene-3, Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal B-cell Lymphoma, Lymphoma, Large-Cell, Anaplastic, Burkitt lymphoma, Lymphoblastic lymphoma, NK/ T-cell lymphoma, Peripheral T-cell lymphoma
- Medical subject headings
- Lymphoma, Non-Hodgkin, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Peripheral
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RelatlimabDrug
Also called BMS-986016
Specified Dose on Specified Days
NivolumabDrug
Also called BMS-936558
Specified Dose on Specified Days
| Study group | Role | What they receive |
|---|---|---|
| Relatlimab + Nivolumab | Experimental | Not described Receives: Drug: Relatlimab; Drug: Nivolumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A
Hepatic DLT
- ALT or AST > 8 × ULN
- ALT or AST > 5 and ≤ 8 × ULN, that fails to return to ≤ Grade 1 within 2 weeks despite medical intervention.
- TB > 5 × ULN.
- ALT or AST > 3 × ULN and concurrent total bilirubin > 2 × ULN. Non-Hematologic DLT
- ≥ Grade 2 episcleritis, uveitis, iritis or any other immune-related eye pain or reduction in visual acuity that requires systemic treatment.
- ≥ Grade 3 non-hepatic or non-hematologic toxicity with the exceptions noted below.
Hematologic DLT
- Grade 4 anemia not explained by underlying disease.
- Grade 3 febrile neutropenia lasting > 48 hours, or Grade 4 febrile neutropenia
- Grade 4 neutropenia that does not resolve to Grade 3 or less within 5 days of initiation of granulocyte colony stimulating factor.
- Grade 3 thrombocytopenia associated with clinically significant bleeding.
- Grade 3 hemolysis
Measured: 1 cycle, defined as 28 days
Complete Metabolic Response (CMR) Rate - Part B
The CMR rate is defined as the percentage of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria.
No participants enrolled in Part B.
Measured: From first dose until the first documented response
Number of Participants With Adverse Events (AEs) - Part A
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Measured: From first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants Who Died - Part A
Number of participants who died due to any cause
Measured: from first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Serious Adverse Events (SAEs) - Part A
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Measured: from first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Measured: From first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Laboratory Abnormalities - Part A
Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry.
Grade 3=severe Grade 4=life-threatening Grade 5=death
Measured: From first dose to 30 days post last dose (Up to approximately 8 months)
Maximum Serum Concentration (Cmax)
Maximum observed serum concentration of Analyte BMS-986016
Measured: Cycle 1 Day 1
Time to Maximum Concentration (Tmax)
Time of maximum observed serum concentration of Analyte BMS-986016
Measured: Cycle 1 Day 1
Area Under the Concentration-time Curve [AUC(TAU)]
Area Under the Concentration-time Curve [AUC(TAU)] for Analyte BMS-986016
Measured: Cycle 1 Day 1
Concentration Trough (Ctrough)
Concentration Trough (Ctrough) for Analyte BMS-986016 and BMS-936558
Measured: Cycle 2 Day 1, Cycle 4 Day 1, Cycle 6 Day 1
Secondary outcomes (6)
Number of Participants With Adverse Events (AEs) - Part B
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
No participants enrolled in part B.
Measured: From first dose to 135 days post last dose
Number of Participants With Serious Adverse Events (SAEs) - Part B
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
No participants enrolled in part B.
Measured: From first dose to 135 days post last dose
Number of Participants With Adverse Events Leading to Discontinuation - Part B
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
No participants enrolled in part B.
Measured: From first dose to 135 days post last dose
Number of Participants Who Died - Part B
Number of participants who died due to any cause. No participants enrolled in part B.
Measured: From first dose to 135 days post last dose
Number of Participants With Laboratory Abnormalities - Part B
No participants enrolled in part B.
Measured: From first dose to 135 days post last dose
Objective Response Rate (ORR) - Part B
ORR is defined as the percentage of all response evaluable participants who achieve a best response of CMR or PMR using the Lugano 2014 classification.
No participants enrolled in part B
Measured: From to
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2022
- Study start13 Sep 2022
- Primary completion3 Dec 2025
- Study completion3 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Lymphoma, Non-HodgkinStudies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05255601
- Sponsor's protocol ID
- CA224-069
- Other IDs
- 2023-503715-14, U1111-1264-4062, 2023
- Acronym
- RELATIVITY-069
- Status last verified
- Jun 2026
- First submitted
- 15 Feb 2022
- Last updated
- 26 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Expanded access
- Available
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
- ClinicalTrials.gov ID
- NCT05255601
- Acronym / sponsor ID
- RELATIVITY-069 / CA224-069
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Disease
- Keywords
- Pediatric, Lymphoma, Non-Hodgkin, Hodgkin Disease, Relatlimab, Nivolumab, Lymphocyte Activation Gene-3, Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal B-cell Lymphoma
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Bristol-Myers SquibbIndustry (pharma, biotech, devices)
- Study start
- 13 Sep 2022 (actual)
- Primary completion
- 3 Dec 2025 (actual)
- Study completion
- 3 Dec 2025 (actual)
- First posted
- 24 Feb 2022 (actual)
- Results
- Posted 26 Jun 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Relatlimab + Nivolumab | Experimental | Drug: Relatlimab, Drug: Nivolumab |
Who may qualify
- Ages
- Up to 30 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Participants with pathologically confirmed high-risk R/R cHL, after non-response to or failure of 1or more lines of standard therapy.
- Participants with pathologically confirmed R/R NHL after non-response to or failure of 1or more lines of standard therapy, including, but not limited to, R/R primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).
- Participants with pathologically confirmed R/R NHL after non-response to or failure of 2 or more lines of standard therapy, including Burkitt lymphoma (blast count <25% malignant Burkitt cells and/or per the investigator's clinical assessment of risk status), lymphoblastic lymphoma (blast count < 25% of marrow nucleated cells and/or per the investigator's clinical assessment of risk status), NK/T-cell lymphoma (nasal and non-nasal NK/T-cell lymphoma subtypes, but not aggressive NK/T-cell leukemia/lymphoma subtype).
- The participant's current disease state must be R/R to standard therapy.
- Participants must have measurable PET positive disease in both cHL and NHL cohorts.
Key exclusion criteria (7 listed)
- Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding.
- Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies.
- Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents.
- Participants with clinically significant systemic illnesses unrelated to the cancer as judged by the investigators, which would compromise the participant's ability to tolerate the study treatment.
- Participants with autoimmune disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RelatlimabAlso: BMS-986016Specified Dose on Specified Days | Drug | Relatlimab + Nivolumab |
| NivolumabAlso: BMS-936558Specified Dose on Specified Days | Drug | Relatlimab + Nivolumab |
Primary outcome
Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A
Time frame: 1 cycle, defined as 28 days
Hepatic DLT * ALT or AST > 8 × ULN * ALT or AST > 5 and ≤ 8 × ULN, that fails to return to ≤ Grade 1 within 2 weeks despite medical intervention. * TB > 5 × ULN. * ALT or AST > 3 × ULN and concurrent total bilirubin > 2 × ULN. Non-Hematologic DLT * ≥ Grade 2 episcleritis, uveitis, iritis or any other immune-related eye pain or reduction in visual acuity that requires systemic treatment. * ≥ Grade 3 non-hepatic or non-hematologic toxicity with the exceptions noted below. Hematologic DLT * Grade 4 anemia not explained by underlying disease. * Grade 3 febrile neutropenia lasting > 48 hours, or Grade 4 febrile neutropenia * Grade 4 neutropenia that does not resolve to Grade 3 or less within 5 days of initiation of granulocyte colony stimulating factor. * Grade 3 thrombocytopenia associated with clinically significant bleeding. * Grade 3 hemolysis
Complete Metabolic Response (CMR) Rate - Part B
Time frame: From first dose until the first documented response
The CMR rate is defined as the percentage of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria. No participants enrolled in Part B.
Number of Participants With Adverse Events (AEs) - Part A
Time frame: From first dose to 135 days post last dose (Up to approximately 11 months)
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Number of Participants Who Died - Part A
Time frame: from first dose to 135 days post last dose (Up to approximately 11 months)
Number of participants who died due to any cause
Number of Participants With Serious Adverse Events (SAEs) - Part A
Time frame: from first dose to 135 days post last dose (Up to approximately 11 months)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A
Time frame: From first dose to 135 days post last dose (Up to approximately 11 months)
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
Number of Participants With Laboratory Abnormalities - Part A
Time frame: From first dose to 30 days post last dose (Up to approximately 8 months)
Number of participants with Grade ≥ 3 laboratory abnormalities in hematology and serum chemistry. Grade 3=severe Grade 4=life-threatening Grade 5=death
Maximum Serum Concentration (Cmax)
Time frame: Cycle 1 Day 1
Maximum observed serum concentration of Analyte BMS-986016
Time to Maximum Concentration (Tmax)
Time frame: Cycle 1 Day 1
Time of maximum observed serum concentration of Analyte BMS-986016
Area Under the Concentration-time Curve [AUC(TAU)]
Time frame: Cycle 1 Day 1
Area Under the Concentration-time Curve [AUC(TAU)] for Analyte BMS-986016
Concentration Trough (Ctrough)
Time frame: Cycle 2 Day 1, Cycle 4 Day 1, Cycle 6 Day 1
Concentration Trough (Ctrough) for Analyte BMS-986016 and BMS-936558
6 secondary outcomes
Number of Participants With Adverse Events (AEs) - Part B
Time frame: From first dose to 135 days post last dose
Number of Participants With Serious Adverse Events (SAEs) - Part B
Time frame: From first dose to 135 days post last dose
Number of Participants With Adverse Events Leading to Discontinuation - Part B
Time frame: From first dose to 135 days post last dose
Number of Participants Who Died - Part B
Time frame: From first dose to 135 days post last dose
Number of Participants With Laboratory Abnormalities - Part B
Time frame: From first dose to 135 days post last dose
Objective Response Rate (ORR) - Part B
Time frame: From to
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- BMS Clinical Trial InformationLink provided by the sponsor.
- BMS Clinical Trial Patient RecruitingLink provided by the sponsor.
Related trials for Lymphoma, Non-Hodgkin
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
Active, not recruitingObservational study
Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma
Extranodal NK/T-cell Lymphoma, Nasal Type
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
51 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Relatlimab and Nivolumab in people with Lymphoma, Non-Hodgkin and Hodgkin Disease, run by Bristol-Myers Squibb at 51 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 51 sites in United States, Italy, Spain, France, United Kingdom and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A (time frame: 1 cycle, defined as 28 days). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.